Graft Polymer (UK) PLC Notice of GM and proposed name change

RNS Number : 6053O

Graft Polymer (UK) PLC

03 December 2024

 

 

 

 03 December 2024

Graft Polymer (UK) Plc
(the "Company")

 

Proposed change of name to Solvonis Therapeutics Plc

 

Continuing progress with the Awakn collaboration

 

Proposed change of name

 

Graft Polymer (UK) Plc (LON:GPL) announces its intention to change its name to Solvonis Therapeutics Plc, subject to approval of its shareholders at a general meeting of the Company (the "GM"), to be held at  Eccleston Yards, 25 EP, Victoria, London, SW1W 9NF on 6 January, 2025 at 1:00pm GMT.  This resolution will be proposed as a special resolution. 

 

The proposed name, "Solvonis Therapeutics Plc" aligns more closely with the Company's strategic focus on developing intellectual property and co-developing therapeutics to address mental health and substance use disorders.

 

"Solvonis" reflect the Company's mission to improve outcomes for individuals and families affected by mental health and substance use disorders. The Company's initial focus is on trauma-related mental health disorders, such as post-traumatic stress disorder ("PTSD"). This mission will continue to be executed through the Company's previously stated plan of joint ventures, strategic partnerships, and mergers and acquisitions.

 

The proposed name change will be presented as a special resolution at the GM. Details of the GM, including the time and venue, will be included in the Notice of the General Meeting, which has been dispatched to shareholders today and made available on the Company's website. 

 

The Board of Directors unanimously supports the proposed name change, believing it aligns with the Company's strategic objectives and serves the best interests of the Company and its shareholders. The Board recommends that shareholders vote in favour of the resolution to be proposed at the GM. 

 

 

Continuing Progress with the Awakn Collaboration

 

The Company is pleased to report continued progress in its Aminoindane New Chemical Entity (NCE) collaboration with Awakn, originally announced on 18 July 2024. This collaboration represents an important step in the Company's efforts to advance innovative therapeutics for mental health. Results from the initial studies, conducted in partnership with Eurofins Discovery and the University of Nottingham, are expected to be reported imminently, marking a key development in the programme.

 

Charnwood Discovery, Awakn's selected synthesis partner (announced on 28 August 2024), was acquired by Concept Life Sciences on 5 November 2024. Awakn has confirmed that its collaboration will continue with Concept Life Sciences, ensuring a smooth transition for any further synthesis activities required to advance the Aminoindane NCE programme. These developments highlight the continued momentum and focus on delivering progress within this promising area of therapeutic research.

 

 

Enquiries:

 

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. [e-mail]

 

Allenby Capital (Broker) [phone]

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.

 

For more information, please visit www.graftpolymer.co.uk.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NOGKXLBBZLLZFBB